Bharat Biotech

Indian multinational biotechnology company and vaccine manufacturer

Bharat Biotech ▸ Facts ▸ Comments ▸ News ▸ Videos

Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company headquartered in the city of Hyderabad, India engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products.

0 shares	Share Tweet Save Post Send


Health Minister launches India’s first nasal COVID-19 vaccine ‘iNCOVACC’ \| Oneindia News Union Health Minister Dr Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched India's first nasal COVID-19 vaccine - 'iNCOVACC' on Thursday. The nasal COVID-19 vaccine has been.. Credit: Oneindia Duration: 01:58Published 14 hours ago

Bharat Biotech to launch first ever intranasal Covid-19 vaccine on 26th January\| Oneindia News *News India’s vaccine manufacturer Bharat Biotech to launch first ever intranasal Covid-19 vaccine on 26th January. #Covid19vaccine #BharatBioTech #NasalVaccine Credit: Oneindia Duration: 01:45Published 5 days ago

UN records almost 18,000 civilian casualties in Ukraine since Russian invasion \| Oneindia News*News Bharat Biotech's nasal vaccine to be available on CoWIN app from today; Shelly Oberoi named Delhi Mayor candidate of AAP; People advised to wear masks by government, it’s not mandatory for now;.. Credit: Oneindia Duration: 02:37Published on December 28, 2022

Covid drills held across cities, Hospital checks conducted \| Oneindia News *News Covid drills held across cities, Hospital checks conducted; Bharat Biotech announces price of intranasal Covid vaccine; The 6th edition of the joint exercise of the Indian Army & Kazakhstan Army KazInd.. Credit: Oneindia Duration: 03:28Published on December 27, 2022

Bharat Biotech's intranasal Covid vaccine to be available on CO-WIN from today \| Oneindia News*News Bharat Biotech's nasal vaccine to be available on CoWIN app from today; Shelly Oberoi named Delhi Mayor candidate of AAP; People advised to wear masks by government, it’s not mandatory for now;.. Credit: Oneindia Duration: 02:25Published on December 23, 2022

You Might Like

Covid-19: Health Minister launches Bharat Biotech's first India-made nasal vaccine, all you need to know The first nasal Covid-19 vaccine developed in India by Bharat Biotech, iNCOVACC launches on the 74th Republic Day. DNA - Published 17 hours ago
Centre launches Bharat Biotech's iNCOVACC, India's first nasal Covid vaccine On the occasion of Republic Day, India got its first-ever intranasal vaccine iNCOVACC, which will be manufactured by Hyderabad-based Bharat Biotech.The vaccine, dubbed "game changer" by some experts,.. IndiaTimes - Published 17 hours ago
India gets first nasal Covid vaccine: How it can be the 'game changer' Centre on Thursday launched India's first nasal Covid-19 vaccine iNCOVACC. Bharat Biotech's Incovacc received government approval for use as a booster dose in the country-wide mass inouclation program... IndiaTimes - Published 18 hours ago

Covid-19: Bharat Biotech's iNCOVACC nasal vaccine to hit markets from February; know prices, eligibility Bharat Biotech's iNCOVACC will be the country of India's first needleless booster shot which will be available in private hospitals. DNA - Published 4 days ago
First nasal vaccine for Covid-19, Bharat Biotech's iNCOVACC, to be launched on January 26 Bharat Biotech will offer the intranasal vaccine for Rs 325 to the government and Rs 800 to private hospitals. DNA - Published 6 days ago
First Indian intranasal Covid vaccine to be launched on January 26 Homegrown vaccine maker Bharat Biotech will launch its intranasal Covid-19 vaccine iNCOVACC, the first of its kind in India, on January 26, the company's chairman and managing director Krishna Ella.. IndiaTimes - Published 6 days ago

Ocugen-Bharat Biotech Covid vaccine Covaxin meets main goals in US trial Ocugen Inc said on Monday the Covid-19 vaccine developed by its Indian partner Bharat Biotech International Ltd met the main goals of a trial in the United States. The vaccine, sold under brand name.. IndiaTimes - Published 3 weeks ago
Amid Covid BF.7 scare in India, know who is eligible to get Bharat Biotech nasal vaccine booster dose The booster dose of the Bharat Biotech intranasal Covid vaccine is now available on the CoWIN platform and can be booked by eligible populations. DNA - Published on December 28, 2022
Bharat Biotech's nasal vaccine at Rs 800 for private centres and Rs 325 for govt hospitals Bharat Biotech’s intranasal Covid-19 vaccine iNCOVACC will be priced at Rs 800 per dose in private markets and at Rs 325 per dose for procurement by central and state governments, the vaccine maker.. IndiaTimes - Published on December 27, 2022
Covid 4th wave scare in India: Bharat Biotech reveals price of nasal vaccine, check how to book booster dose online Bharat Biotech has revealed the price of its intranasal Covid vaccine amid 4th wave scares, and the booster dose of the same can been booked online. DNA - Published on December 27, 2022

Bharat Biotech's nasal vaccine to be priced at Rs 800/dose in pvt markets, Rs 325/dose for governments Bharat Biotech on Tuesday said that its intranasal Covid-19 vaccine iNCOVACC will be priced at Rs 800 per dose for the private markets and Rs 325 per dose for central and state governments. The company.. IndiaTimes - Published on December 27, 2022
'Bharat Biotech annonces price of nasal vaccine': Covid-19 key points IndiaTimes - Published on December 27, 2022
Bharat Biotech's nasal Covid vaccine can be used as booster: Regulator IndiaTimes - Published on November 28, 2022	World's first intranasal Covid vaccine from Bharat Biotech gets CDSCO approval iNCOVACC: Bharat Biotech said that launch dates, pricing and availability will be announced in due course of time. DNA - Published on November 28, 2022
Bharat Biotech's intranasal Covid-19 vaccine iNCOVACC gets CDSCO nod for heterologous booster doses IndiaTimes - Published on November 28, 2022Also reported by •DNA	Bharat Biotech's Intranasal Covid-19 Booster gets DCGI nod for emergency use For individuals 18 years of age and older, the DCGI has authorised the use of Bharat Biotech's five arms heterologous booster, ANI reported. DNA - Published on November 25, 2022
Indian govt, Bharat Biotech rubbish reports of Covaxin development being rushed under political pressure IndiaTimes - Published on November 17, 2022	Bharat Biotech's Covid-19 nasal vaccine approved for restricted use in India Bharat Biotech's Covid-19 recombinant nasal vaccine has been approved by the Indian drug regulator, the country's health minister Mansukh Mandaviya tweeted on Tuesday. IndiaTimes - Published on September 6, 2022Also reported by •DNA
Bharat Biotech submits intranasal vaccine data to drug regulator, says vax safe and immunogenic Bharat Biotech International Limited (BBIL) on Monday said its intranasal Covid-19 vaccine BBV154 has proved to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials for.. IndiaTimes - Published on August 15, 2022	Bharat Biotech expects regulator's nod for intranasal Covid-19 vaccine in August Bharat Biotech, which is working on an intranasal Covid-19 vaccine candidate is hopeful of getting regulatory licenses this month, if all goes well, chairman and managing director of the company,.. IndiaTimes - Published on August 2, 2022
Biological E's Corbevax, Bharat Biotech's Covaxin get NTAGI's nod for use children aged 5-12 years Prime Minister Narendra Modi emphasised that all eligible children get the Covid-19 vaccine as soon as possible via "special programmes" in schools. DNA - Published on July 9, 2022	Bharat Biotech's Covid-19 nasal vaccine phase III trials completed In an exclusive interview with ANI, Dr Ella said, "We just completed a clinical trial, a data analysis is going on. Next month, we will submit the data to the regulatory agency. If everything is okay,.. IndiaTimes - Published on June 19, 2022
Covaxin safe for 2-18 age group: BB study It conducted phase II/III, open-label, and multicentre study to evaluate the safety, reactogenicity and immunogenicity of Covaxin in children and adolescents in the 2-18 years of age group between.. IndiaTimes - Published on June 17, 2022	Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR study The protective efficacy of Bharat Biotech's Covaxin following two and three-dose immuniszations against the Delta variant and the efficacy of the Covaxin against Omicron variants were studied in a.. IndiaTimes - Published on June 15, 2022
FDA lifts hold on Covaxin's clinical trials in US The US Food and Drug Administration which has put on hold the phase 2/ 3 clinical trials of Bharat Biotech's Covid-19 vaccine Covaxin, in USA, has lifted the pause, according to a statement issued by.. IndiaTimes - Published on May 24, 2022	Covaxin Phase 2&3 trials to resume in US after USFDA lifts clinical hold The US Food and Drug Administration (USFDA) has lifted the clinical hold on the Phase 2 and 3 immuno-bridging clinical trials of Bharat Biotech’s Covid-19 vaccine Covaxin that were being conducted in.. IndiaTimes - Published on May 23, 2022
CEPI partners consortium of Bharat Biotech, Sydney University & ExcellGene to develop variant-proof SARS-CoV-2 vaccine IndiaTimes - Published on May 10, 2022	Bharat Biotech seeks DCGI nod for phase 2/3 Covaxin booster trial among two to 18-year-old Bharat Biotech has sought permission from India's drug regulator to conduct a phase 2/3 study of its Covid vaccine Covaxin as a booster dose among those aged two to 18 years, sources told PTI... IndiaTimes - Published on May 4, 2022
MEA asked Bharat Biotech to act on WHO suspension? Officials refute claim IndiaTimes - Published on April 29, 2022	Bharat Biotech must address WHO's Covaxin suspension to avoid EUL cancellation, says MEA Weeks after WHO suspended the supply of Covaxin through UN procurement agencies, the MEA suggested that vaccine-maker Bharat Biotech addresses the issue immediately to avoid cancellation of the world.. IndiaTimes - Published on April 28, 2022
DCGI gives approval for Bharat Biotech's Covaxin for children aged 6-12 The Drug Controller General of India (DCGI) has given a restricted emergency use approval for Bharat Biotech's Covid-19 vaccine, Covaxin, for children between the age of six and 12. A Subject Expert.. IndiaTimes - Published on April 26, 2022Also reported by •DNA	DCGI grants approval to Corbevax for kids aged 5-12, Covaxin for 6-12 age group The Drug Controller General of India (DCGI) on Tuesday granted emergency use approval to Covid-19 vaccines, Covaxin and Corbevax, for children below 12. Bharat Biotech's Covaxin has got nod for use in.. IndiaTimes - Published on April 26, 2022
Bharat Biotech asked to provide more data on Covid-19 vaccine Covaxin for children aged below 12 The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has asked Bharat Biotech for additional data on its Covid-19 vaccine, Covaxin, for administering it to children aged.. IndiaTimes - Published on April 22, 2022	Fallout of WHO observations: Covaxin's Phase 2/3 trials in US put on hold The US Food and Drug Administration has put on hold the phase 2/3 clinical trials of Bharat Biotech's Covid-19 vaccine Covaxin, in USA. Bharat Biotech's partner for US and Canada for Covaxin, the FDA's.. IndiaTimes - Published on April 14, 2022
Bharat Biotech, SII slash prices of Covaxin, Covishield booster dose to Rs 225 per shot IndiaTimes - Published on April 9, 2022	Covishield, Covaxin prices slashed ahead of booster drive expansion Serum Institute of India has reduced the price of its Covishield vaccine from Rs 600 to Rs 225 per dose for private hospitals, the vaccine maker announced on Saturday. Bharat Biotech also slashed the.. IndiaTimes - Published on April 9, 2022
Japan recognises Covaxin to facilitate travel from April 10: Bharat Biotech IndiaTimes - Published on April 8, 2022	'Amid drop in demand, Bharat Biotech slowed Covaxin production since February' IndiaTimes - Published on April 5, 2022
No impact of WHO action on Covaxin, have not supplied to any UN agency: Bharat Biotech With WHO announcing the suspension of Covaxin supply through UN procurement agencies, Bharat Biotech sources said on Monday the pharma company has not supplied the COVID-19 vaccine to any UN agency and.. IndiaTimes - Published on April 4, 2022	SII's Covovax becomes the fourth jab to be used for vaccination of 12-17 age group Covovax is the 4th Covid vaccine authorised for administration in 12 years and above after ZyCoV-D, Bharat Biotech's Covaxin, Biological E's Corbevax. DNA - Published on April 4, 2022
WHO suspends Covaxin supply for UN procurement citing GMP deficiencies at Bharat Biotech facilities IndiaTimes - Published on April 2, 2022	Will Covid-19 nasal vaccine prove effective against infection? AIIMS expert says THIS AIIMS expert Dr Sanjay Rai talked about the effectiveness of the Bharat Biotech nasal vaccine against the Covid-19 infection. DNA - Published on January 31, 2022
Covaxin showed better antibody response in 2-18 year olds than adults: Bharat Biotech IndiaTimes - Published on December 30, 2021	'Precautionary dose' for 60+ with comorbidities 9 months after 2nd dose - Check new guidelines Bharat Biotech's Covaxin has been granted approval for restricted use in an emergency situation in the age group between 12 and 18 years. DNA - Published on December 28, 2021
Documents required to register children between 15-18 years on CoWIN App - Complete list here Meanwhile, Bharat Biotech received the nod from the DGCI for emergency use of vaccines in children above the age of 12 years. DNA - Published on December 27, 2021	BREAKING: Bharat Biotech gets DGCI approval for emergency vaccination for kids aged 12-18 Amid rising cases of Omicron in India, DGCI has given Bharat Biotech a green signal for the emergency use of its vaccine for kids aged between 12 to 18 years. DNA - Published on December 25, 2021
Bharat Biotech seeks DCGI's nod for its intranasal COVID-19 booster dose clinical trials The company is hoping for early approval for the trails of the intranasal COVID-19 booster given the fast spread of the Omicron variant. DNA - Published on December 20, 2021Also reported by •IndiaTimes	Covishield production capacity 250-275 million doses a month, Covaxin 50-60 million: MoS Health The current vaccine production capacity of Covishield, manufactured by the Serum Institute of India, is approximately 250-275 million doses per month while it is about 50-60 million doses per month for.. IndiaTimes - Published on December 14, 2021

Bharat Biotech

Indian multinational biotechnology company and vaccine manufacturer

Bharat Biotech ▸ Facts ▸ Comments ▸ News ▸ Videos

You Might Like

Covid-19: Health Minister launches Bharat Biotech's first India-made nasal vaccine, all you need to know

Centre launches Bharat Biotech's iNCOVACC, India's first nasal Covid vaccine

India gets first nasal Covid vaccine: How it can be the 'game changer'

Covid-19: Bharat Biotech's iNCOVACC nasal vaccine to hit markets from February; know prices, eligibility

First nasal vaccine for Covid-19, Bharat Biotech's iNCOVACC, to be launched on January 26

First Indian intranasal Covid vaccine to be launched on January 26

Ocugen-Bharat Biotech Covid vaccine Covaxin meets main goals in US trial

Amid Covid BF.7 scare in India, know who is eligible to get Bharat Biotech nasal vaccine booster dose

Bharat Biotech's nasal vaccine at Rs 800 for private centres and Rs 325 for govt hospitals

Covid 4th wave scare in India: Bharat Biotech reveals price of nasal vaccine, check how to book booster dose online

Bharat Biotech's nasal vaccine to be priced at Rs 800/dose in pvt markets, Rs 325/dose for governments

'Bharat Biotech annonces price of nasal vaccine': Covid-19 key points

Bharat Biotech's nasal Covid vaccine can be used as booster: Regulator

World's first intranasal Covid vaccine from Bharat Biotech gets CDSCO approval

Bharat Biotech's intranasal Covid-19 vaccine iNCOVACC gets CDSCO nod for heterologous booster doses

Bharat Biotech's Intranasal Covid-19 Booster gets DCGI nod for emergency use

Indian govt, Bharat Biotech rubbish reports of Covaxin development being rushed under political pressure

Bharat Biotech's Covid-19 nasal vaccine approved for restricted use in India

Bharat Biotech submits intranasal vaccine data to drug regulator, says vax safe and immunogenic

Bharat Biotech expects regulator's nod for intranasal Covid-19 vaccine in August

Biological E's Corbevax, Bharat Biotech's Covaxin get NTAGI's nod for use children aged 5-12 years

Bharat Biotech's Covid-19 nasal vaccine phase III trials completed

Covaxin safe for 2-18 age group: BB study

Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR study

FDA lifts hold on Covaxin's clinical trials in US

Covaxin Phase 2&3 trials to resume in US after USFDA lifts clinical hold

CEPI partners consortium of Bharat Biotech, Sydney University & ExcellGene to develop variant-proof SARS-CoV-2 vaccine

Bharat Biotech seeks DCGI nod for phase 2/3 Covaxin booster trial among two to 18-year-old

MEA asked Bharat Biotech to act on WHO suspension? Officials refute claim

Bharat Biotech must address WHO's Covaxin suspension to avoid EUL cancellation, says MEA

DCGI gives approval for Bharat Biotech's Covaxin for children aged 6-12

DCGI grants approval to Corbevax for kids aged 5-12, Covaxin for 6-12 age group

Bharat Biotech asked to provide more data on Covid-19 vaccine Covaxin for children aged below 12

Fallout of WHO observations: Covaxin's Phase 2/3 trials in US put on hold

Bharat Biotech, SII slash prices of Covaxin, Covishield booster dose to Rs 225 per shot

Covishield, Covaxin prices slashed ahead of booster drive expansion

Japan recognises Covaxin to facilitate travel from April 10: Bharat Biotech

'Amid drop in demand, Bharat Biotech slowed Covaxin production since February'

No impact of WHO action on Covaxin, have not supplied to any UN agency: Bharat Biotech

SII's Covovax becomes the fourth jab to be used for vaccination of 12-17 age group

WHO suspends Covaxin supply for UN procurement citing GMP deficiencies at Bharat Biotech facilities

Will Covid-19 nasal vaccine prove effective against infection? AIIMS expert says THIS

Covaxin showed better antibody response in 2-18 year olds than adults: Bharat Biotech

'Precautionary dose' for 60+ with comorbidities 9 months after 2nd dose - Check new guidelines

Documents required to register children between 15-18 years on CoWIN App - Complete list here

BREAKING: Bharat Biotech gets DGCI approval for emergency vaccination for kids aged 12-18

Bharat Biotech seeks DCGI's nod for its intranasal COVID-19 booster dose clinical trials

Covishield production capacity 250-275 million doses a month, Covaxin 50-60 million: MoS Health